At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
TJ004309drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating TJ004309 for Ovarian Cancer and 5 related conditions. Completed, enrolled 25 participants across 15 sites.
Detailed Summary
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartNov 2021
Primary CompletionFeb 2023
TodayJul 2026
First PostedAug 11, 2021
Enrollment StartNov 2, 2021
Primary CompletionFeb 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.9 years ago
Interventions
TJ004309drug
Antibody to CD73